Cellectis (CLLS) Analyst Targets Point to a Large Upside After the Pivot

Key Takeaways

• The central price target of $4.10 is the arithmetic mean of the three verified post-pivot analyst price targets: $1.30 (Barclays), $3.00 (Wells Fargo), and $8.00 (Robert W. Baird).
• The CLLS ADR recently traded near $1.03, meaning the stock would need to climb roughly 298% to reach the $4.10 target — a very large move.
• Analyst views are unusually divided after Cellectis's September 2026 strategic pivot away from CAR-T cancer therapies toward in vivo gene editing, producing a wide $1.30-to-$8.00 target range.
• Key supports include roughly $169 million in cash against a market value near $100 million, a cash runway extended into the second half of 2028, and retained partnerships with AstraZeneca, Allogene, Servier, and Iovance.
• The biggest risks are the loss of de-risked late-stage programs, clinical data now expected no earlier than late 2027, a crowded cardiometabolic field, and a share price hovering near the $1.00 Nasdaq minimum-bid level.
• You can find more on this ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages.
• Explore Trending AI Robots to see AI-driven strategies scanning thousands of tickers for changing opportunities.

Analyst Views After the Pivot

Cellectis S.A. (CLLS) is a Paris-based clinical-stage gene-editing biotechnology company whose American depositary receipts trade on the Nasdaq. Following the company's September 2026 decision to discontinue its CAR-T programs lasme-cel and eti-cel and refocus on in vivo gene editing, three analysts issued current price targets: Barclays' Lukas Shumway downgraded the shares to Underweight with a $1.30 target; Wells Fargo's Nick Abbott kept an Equal Weight rating and cut his target to $3.00; and Robert W. Baird's Jack Allen lowered his target to $8.00. The arithmetic mean of these three valid targets is $4.10, within a wide $1.30-to-$8.00 range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Older, pre-pivot targets — such as a $9.00 objective from Barclays and Clear Street and a $7.00 target from Jefferies — were treated as stale because they predate the company's fundamental repositioning. The dispersion among the three current targets reflects genuine disagreement: the bearish view argues the pivot leaves a preclinical, unproven story, while the bullish view sees optionality in Cellectis's TALEN-based in vivo platform. This is not a tightly clustered analyst consensus, and the mean should not be read as a guarantee.

Where the Stock Stands Today

With the ADR recently near $1.03, reaching $4.10 would require roughly a 298% gain — a very large move by any standard. The stock sits near the bottom of a 52-week range of approximately $0.88 to $5.45, having shed roughly 40% in a single session after the strategic announcement. The path toward the target would depend on early human data for the new pipeline: HEAL-101, a TALE base-editor targeting APOC3 for severe hypertriglyceridemia, and HEAL-201, targeting PCSK9 for severe hypercholesterolemia. Preliminary Phase 1 data are not expected until the second half of 2027 and first half of 2028, respectively, so the near-term story is primarily one of cash preservation, partnerships, and preclinical validation.

Factors That Could Drive Gains

Several factors could underpin a recovery. Cellectis reported roughly $169 million in cash as of June 30, 2026, against a market capitalization near $100 million, leaving the shares trading near or below net cash value. The restructuring is expected to extend the cash runway into the second half of 2028. The company is retaining its cell-therapy collaborations with AstraZeneca, Allogene, Servier, and Iovance, which may generate milestone economics while the internal pipeline matures. In vivo gene editing for cardiometabolic disease is attracting substantial investor interest, and Cellectis's proprietary TALEN platform offers differentiation. Positive early biomarker or safety data in 2027 could materially reset the risk-reward calculus that currently anchors cautious targets.

Risks on the Horizon

The obstacles are substantial. The pivot abandons lasme-cel and eti-cel at a time when those programs had shown strong response rates and received regulatory designations, removing the nearest measurable catalysts. Clinical readouts are now more than a year away, and Barclays has questioned the preclinical data presented so far. The new indications are competitive: the APOC3 field already includes an approved therapy (plozasiran), and the PCSK9 space has established in vivo competitors. With negative earnings per share and no near-term profitability, the shares also face the technical risk of Nasdaq minimum-bid compliance concerns while trading near $1.00.

Technical Picture

The shares' collapse reset the technical picture. The 52-week low near $0.88 stands as the key downside reference, while the $1.00 level carries both psychological and listing-compliance significance. On the upside, the stock must first reclaim the pre-pivot levels it surrendered in the low-to-mid $2.00 area before any credible move toward the higher analyst targets becomes visible; the prior 52-week high near $5.45 sits above even the highest current target.

What to Watch Going Forward

Analyst price targets generally reflect a research horizon of roughly 12 months, though the specific horizons differ by firm, and Cellectis's own catalysts extend well beyond that window. Investors should watch for quarterly earnings updates and any commentary on cash runway and partnership milestones, plus preclinical or non-human-primate data that analysts such as Wells Fargo have flagged as de-risking events. Regulatory and trial-initiation announcements for HEAL-101 and HEAL-201 in China, and any signs of Nasdaq minimum-bid compliance actions, are also directly relevant to the target debate. From what I see, monitoring these milestones will be key to assessing whether the story can regain traction.

AI Daily Buy/Sell Signals

In my own research process, Tickeron's AI Daily Buy/Sell Signals provide a useful way to track momentum shifts across many names. The system applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a name like CLLS that can move quickly on pipeline developments, this kind of real-time perspective helps keep the broader context in view as events unfold.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume